Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53null Cell Lines

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Silden, Elisabeth ^a   Hjelle, Sigrun M ^a   Wergeland, Line ^a   Sulen, André ^a   Andresen, Vibeke ^a   Bourdon, Jean Christophe ^b   Micklem, David R ^a   McCormack, Emmet ^a   Gjertsen, Bjørn Tore ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CAMPTOTHECIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DICOUMAROL; DNA; DOXORUBICIN; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53; PROTEIN P53 BETA; PROTEIN P53 GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CHEMOSENSITIVITY; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG RESPONSE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE DELETION; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MICE; OSTEOSARCOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873617846     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056276     Document Type: Article

References (35)

1. Khoury MP, Bourdon JC, (2010) The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2: a000927.
2. Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, et al. (2010) Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. FEBS Lett 584: 4463-4468.
3. Bourdon JC, (2007) p53 and its isoforms in cancer. Br J Cancer 97: 277-282.
4. Wei J, Zaika E, Zaika A, (2012) p53 Family: Role of Protein Isoforms in Human Cancer. J Nucleic Acids 2012: 687359.
5. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, et al. (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19: 2122-2137.
6. Anensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, et al. (2012) Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene 31: 1533-1545.
7. Sellmann L, Carpinteiro A, Nuckel H, Scholtysik R, Siemer D, et al. (2012) p53 protein expression in chronic lymphocytic leukemia. Leuk Lymphoma. 53.1282-1288.
8. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, et al. (2011) p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 13: R7.
9. Song W, Huo SW, Lu JJ, Liu Z, Fang XL, et al. (2009) Expression of p53 isoforms in renal cell carcinoma. Chin Med J (Engl) 122: 921-926.
10. Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, et al. (2010) Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene 29: 1997-2004.
11. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K, (2007) Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 43: 617-623.
12. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT, (2000) Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 20: 8458-8467.
13. Camus S, Menendez S, Fernandes K, Kua N, Liu G, et al. (2012) The p53 isoforms are differentially modified by Mdm2. Cell Cycle 11: 1646-1655.
14. Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, et al. (2011) Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 18: 1815-1824.
15. Asher G, Tsvetkov P, Kahana C, Shaul Y, (2005) A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 19: 316-321.
16. Brown JM, Attardi LD, (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5: 231-237.
17. Abbas T, Dutta A, (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414.
18. Gartel AL, (2005) The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res 29: 1237-1238.
19. Khoury MP, Bourdon JC, (2011) p53 Isoforms: An Intracellular Microprocessor? Genes Cancer 2: 453-465.
20. Graupner V, Schulze-Osthoff K, Essmann F, Janicke RU, (2009) Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle 8: 1238-1248.
21. Maddocks OD, Vousden KH, (2011) Metabolic regulation by p53. J Mol Med (Berl) 89: 237-245.
22. Lane D, Levine A, (2010) p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2: a000893.
23. Dang CV, Semenza GL, (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72.
24. Gatenby RA, Gillies RJ, (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
25. Braun F, Bertin-Ciftci J, Gallouet AS, Millour J, Juin P, (2011) Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-x(L) inhibition. PLoS One 6: e23577.
26. Swift S, Lorens J, Achacoso P, Nolan GP, (2001) Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol Chapter 10: Unit 10 17C.
27. Peltonen K, Colis L, Liu H, Jaamaa S, Moore HM, et al. (2010) Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS ONE 5: e12996.
28. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B, (1992) Definition of a consensus binding site for p53. Nat Genet 1: 45-49.
29. Shieh SY, Ikeda M, Taya Y, Prives C, (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
30. Wergeland L, Sjoholt G, Haaland I, Hovland R, Bruserud O, et al. (2007) Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol Cancer 6: 33.
31. Tronstad KJ, Berge K, Flindt EN, Kristiansen K, Berge RK, (2001) Optimization of methods and treatment conditions for studying effects of fatty acids on cell growth. Lipids 36: 305-313.
32. Giaever I, Keese CR, (1993) A morphological biosensor for mammalian cells. Nature 366: 591-592.
33. Wegener J, Keese CR, Giaever I, (2000) Electric cell-substrate impedance sensing (ECIS) as a noninvasive means to monitor the kinetics of cell spreading to artificial surfaces. Exp Cell Res 259: 158-166.
34. McCormack E, Bruserud O, Gjertsen BT, (2005) Animal models of acute myelogenous leukaemia- development, application and future perspectives. Leukemia 19: 687-706.
35. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-6489.